NCT01472614 - Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions

Type-2 Diabetes Mellitus

Interventions

DRUG

DLBS3233

Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)

Trial Locations (2)

Unknown

Private Clinic at Jl. Prof. Dr. Moestopo 164, Surabaya

Surabaya Diabetes and Nutrition Centre, Dr. Soetomo Hospital, Surabaya